Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR
- 1 November 2020
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (9), 1271-1282
- https://doi.org/10.1164/rccm.202002-0369OC
Abstract
Rationale: Animal models have been highly informative for understanding the characteristics, onset, and progression of cystic fibrosis (CF) lung disease. In particular, the CFTR-/- rat has revealed insights into the airway mucus defect characteristic of CF but does not replicate a human-relevant CFTR (cystic fibrosis transmembrane conductance regulator) variant. Objectives: We hypothesized that a rat expressing a humanized version of CFTR and harboring the ivacaftor-sensitive variant G551D could be used to test the impact of CFTR modulators on pathophysiologic development and correction. Methods: In this study, we describe a humanized-CFTR rat expressing the G551D variant obtained by zinc finger nuclease editing of a human complementary DNA superexon, spanning exon 2-27, with a 59 insertion site into the rat gene just beyond intron 1. This targeted insertion takes advantage of the endogenous rat promoter, resulting in appropriate expression compared with wildtype animals. Measurements and Main Results: The bioelectric phenotype of the epithelia recapitulates the expected absence of CFTR activity, which was restored with ivacaftor. Large airway defects, including depleted airway surface liquid and periciliary layers, delayed mucus transport rates, and increased mucus viscosity, were normalized after the administration of ivacaftor. Conclusions: This model is useful to understand the mechanisms of disease and the extent of pathology reversal with CFTR modulators.This publication has 48 references indexed in Scilit:
- Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lungNature, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- New animal models of cystic fibrosisCurrent Opinion in Pulmonary Medicine, 2011
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences of the United States of America, 2011
- Loss of Anion Transport without Increased Sodium Absorption Characterizes Newborn Porcine Cystic Fibrosis Airway EpitheliaCell, 2010
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationThe New England Journal of Medicine, 2010
- Cystic Fibrosis Pigs Develop Lung Disease and Exhibit Defective Bacterial Eradication at BirthScience Translational Medicine, 2010
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences of the United States of America, 2009
- Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn PigsScience, 2008
- A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilmsProceedings of the National Academy of Sciences of the United States of America, 2006